Literature DB >> 31828904

Patient-tailored SyncAV algorithm: A novel strategy to improve synchrony and acute hemodynamic response in heart failure patients treated by cardiac resynchronization therapy.

Jingfeng Wang1, Yixiu Liang1, Haiyan Chen2, Wei Wang1, Jin Bai1, Xueying Chen1, Shengmei Qin1, Yangang Su1, Junbo Ge1.   

Abstract

INTRODUCTION: Several automatic algorithms have developed to optimize the timing cycle setting in cardiac resynchronization therapy (CRT). The present study aims to investigate whether the novel device-based SyncAV algorithm could elicit better synchrony and acute hemodynamic response. METHODS AND
RESULTS: Thirty five patients undergoing CRT implantation were prospectively studied. The device was programmed to three biventricular (BiV) pacing modes sequentially after the procedure: QuickOpt algorithm (mode I), SyncAV algorithm with default 50 ms offset (mode II), and SyncAV algorithm with optimized offset minimizing QRS duration (QRSd) (mode III). After each setting, electrocardiographic and echocardiographic data were collected. As a result, QRSd was reduced from 172.8 ± 17.9 ms during intrinsic conduction to 153.1 ± 15.9 ms in mode I, further narrowed to 140.5 ± 16.7 ms in mode II, and reached shortest (134.8 ± 16.1 ms) in mode III (P < .01 for all). Besides, significantly shorter QT intervals were observed in mode I (453.2 ± 45.5 ms), mode II (443.9 ± 34.2 ms) and mode III (444.1 ± 28.7 ms), compared with native condition (472.5 ± 51.2 ms) (P < .01). All three BiV modes exhibited comparable Tp Te interval and Tp Te /QT ratio (P > .05). Mode I presented significantly higher aortic velocity time integral than intrinsic conduction (21.0 ± 6.4 cm vs 18.4 ± 5.5 cm; P < .01), which was even higher in mode II (22.0 ± 6.5 cm) and mode III (23.7 ± 6.5 cm). All three BiV modes significantly reduced standard deviation of time to peak contraction of 12-LV segments (Ts-SD) (Mode I: 55.2 ± 16.5 ms, Mode II: 50.2 ± 14.7 ms, Mode III: 45.4 ± 14.4 ms) compared with intrinsic conduction (66.3 ± 18.4 ms) (P < .01), with Mode III demonstrating the smallest (P < .01).
CONCLUSION: SyncAV CRT ameliorated electrical and mechanical synchrony as well as acute hemodynamic response beyond conventional QuickOpt optimization. An additional individualized adjustment to the SyncAV offset added to its advantage.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  SyncAV algorithm; acute hemodynamic response; cardiac resynchronization therapy; optimization; synchrony

Year:  2019        PMID: 31828904     DOI: 10.1111/jce.14315

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Effect Evaluation of Cardiac Resynchronization Therapy in Elderly Patients with Heart Failure by Ultrasound Image under QuickOpt Algorithm.

Authors:  Na Hu; Na Yi; Huiqiong Yang
Journal:  Comput Math Methods Med       Date:  2022-06-07       Impact factor: 2.809

Review 2.  Cardiac resynchronization therapy in heart failure patients: tough road but clear future.

Authors:  Ziyu Wang; Yongquan Wu; Junmeng Zhang
Journal:  Heart Fail Rev       Date:  2020-10-24       Impact factor: 4.214

3.  Device-based Optimization of Cardiac Resynchronization-One Size Does Not Fit All.

Authors:  Wasim Rashid; Asim Kichloo; Khalil Kanjwal
Journal:  J Innov Card Rhythm Manag       Date:  2022-03-15

4.  Overview of Current Strategies Aiming at Improving Response to Cardiac Resynchronization Therapy.

Authors:  Yakup Yunus Yamantürk; Başar Candemir; Emir Baskovski; Kerim Esenboğa
Journal:  Anatol J Cardiol       Date:  2022-05       Impact factor: 1.475

5.  Inadvertent QRS prolongation by an optimization device-based algorithm in patients with cardiac resynchronization therapy.

Authors:  Kamil Sedláček; Rostislav Polášek; Helena Jansová; Domenico Grieco; Pavel Kučera; Josef Kautzner; Darrel P Francis; Dan Wichterle
Journal:  PLoS One       Date:  2022-09-26       Impact factor: 3.752

Review 6.  Alternative pacing strategies for optimal cardiac resynchronization therapy.

Authors:  Juan Hua; Qiling Kong; Qi Chen
Journal:  Front Cardiovasc Med       Date:  2022-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.